The TRK inhibitor entrectinib is approved in the US and Europe for the treatment of patients with certain types of solid tumors expressing an NTRK gene fusion.624 GC patients with NTRK fusions can also be candidates for NTRK inhibitor therapy,625 but the efficacy of TRK inhibitors in treating GC requires further validation. This evidence concerns the gene NTRK1 and gastric cancer.